Webcast

Hitting Refresh on Excessive Daytime Sleepiness: Managing Patients with Narcolepsy and Idiopathic Hypersomnia

Launch Date
06/14/2021
Credit Amount
0.00 Expired
Credit Expires
06/14/2022

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School
Columbia, SC
Medical University of South Carolina
Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.

Yves Dauvilliers, MD, PhD
Professor of Neurology and Physiology, University of Montpellier
Director, Sleep-Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France
Yves Dauvilliers, MD, PhD

Yves Dauvilliers, MD, PhD, has held the position of Professor of Neurology and Physiology, and Head of the clinical and research activity of the sleep laboratory at the University of Montpellier, France since 2005.  He is also a member of the research group INSERM U1061, and coordinator of the French National Reference Network for Orphan Diseases (Narcolepsy, Hypersomnia, Kleine-Levin Syndrome). He is author or coauthor of more than 370 papers published in international and national peer-reviewed journals, several book chapters. He has also served as editor of three French books related to sleep medicine.

Terri E. Weaver, PhD, RN, FAAN, ATSF, FAASM
Professor Emerita of Biobehavioral Nursing Science, College of Nursing University of Illinois Chicago, Chicago, IL
Professor Emerita of Nursing, University of Pennsylvania, Philadelphia, PA
Terri E. Weaver, PhD, RN, FAAN, ATSF, FAASM

Terri Weaver is dean emerita at the University of Illinois Chicago College of Nursing. She is recognized nationally and internationally for her research on the effect of daytime sleepiness on daily behaviors and assessment of treatment outcomes. Her research career has been honored with many accolades, including induction into the Sigma Theta Tau International Nurse Researcher Hall of Fame. Distinguished as a leader in nursing education, Dr. Weaver was also elected in 2017 to a two-year term on the board of directors of the American Association of Colleges of Nursing. In 2018, she was named to the first class of fellows of the American Thoracic Society.

As a researcher, Dr. Weaver has been supported with funding from the National Institutes of Health, the National Heart, Lung and Blood Institute and the National Institute of Nursing Research. She has produced two notable disease-specific functional status measures, one for chronic pulmonary disorders and the other for sleep disorders. The latter, the Functional Outcomes of Sleep Questionnaire, has become the gold standard for the evaluation of evaluating the impact of treatments for sleep disorders to improve quality of life and; it has been translated into 51 languages and used internationally in clinical trials.

Dr. Weaver earned her BSN at the University of Pittsburgh and her MSN and PhD from the University of Pennsylvania. She is a fellow of the American Academy of Nursing, where she previously served as a member of its Board of Directors. Additionally, she is the Training and Education Chair for the World Federation of Sleep Research & Sleep Medicine Societies and the former chair of the national board of directors of the American Lung Association. She has also held leadership positions in the American Thoracic Society, the American Academy of Sleep Medicine and the Sleep Research Society.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Central disorders of hypersomnia such as narcolepsy and idiopathic hypersomnia (IH) can be debilitating as both disorders are characterized by excessive daytime sleepiness (EDS) which conveys a high degree of disability and burden. While there are safe, effective therapies that promote sustained reduction of symptoms in narcolepsy, there is often a failure to implement them in a timely manner. Moreover, there are currently no FDA-approved treatments for IH, making effective management a challenge. As patients with narcolepsy or IH often experience persistent EDS despite traditional treatment, there is a need for education on identifying and implementing effective novel therapies.

This CME Outfitters webcast features expert faculty will discuss the spectrum of EDS across the subtypes of narcolepsy, strategies to apply data from recent clinical trials to treatment decision-making, and the impact of emerging agents for the management of EDS in patients with IH.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Differentiate the spectrum of EDS across the subtypes of narcolepsy (type 1, type 2).
  • Apply data from recent clinical trials to treatment decision-making in patients with narcolepsy.
  • Evaluate the impact of emerging agents for the management of EDS in patients with IH.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Differentiate the spectrum of EDS across the subtypes of narcolepsy (type 1, type 2).
  • Explain how data from recent clinical trials to treatment decision-making in patients with narcolepsy.
  • Evaluate the impact of emerging agents for the management of EDS in patients with IH.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, physicians, nurse practitioners, PAs, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Dauvilliers reports that he consults for Avadel; Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Theranexus; and UCB S.A., Belgium.

Dr. Weaver reports that she is on the advisory board for Jazz Pharmaceuticals, Inc. She receives other financial support from Functional Outcomes of Sleep Questionnaire (FOSQ) Instrument Licensing Agreement: Bayer AG; Cook Medical; Evidation Health, Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Nyxoah; Philips Resphonics; ResMed; ResMed Germany; RWS; Stratevi; Veerily LIfe Sciences; and WCG MedAvante-ProPhase, Inc.

  • Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
  • Evan Luberger (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-121-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 

 

MMV-115-061421-43

Hitting Refresh on Excessive Daytime Sleepiness: Managing Patients with Narcolepsy and Idiopathic Hypersomnia
Event Date: 06/14/2021